Goodman and Gilman’s. The pharmacological basis of therapeutics, 13th edn. Dec 5, 2017 by Laurence Brunton and Bjorn Knollmann; 2017.
Brownstein MJ. A brief history of opiates, opioid peptides and opioid receptors. Proc Natl Acad Sci USA. 1993;90:5391–3.
Baraka A. Historical aspects of opium. Middle East J Anesthesiol. 2000;15:423–36.
Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol. 1988;3(3):255–66.
Kraeplin E. Manic depressive illness and paranoia. Edinburgh: Livingstone; 1921.
Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. Baltimore: Williams and Wilkins; 1954.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
Tenor Peter L. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49–65.
Contet C, Kieffer BL, Befort K. Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol. 2004;14(3):370–8.
Lutz P, Kieffer B. Opioid receptors: distinct roles in mood disorders. Trends Neurosci. 2013;36(3):195–206.
Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry. 2008;69(suppl E1):4–7.
Svingos AL, Chavkin C, Colago EE, Pickel VM. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse. 2001;42(3):185–92.
Carlezon W Jr, Beguin C, Knoll AT, Cohen BM. Kappa opioid ligands in the study and treatment of mood disorders. Pharmacol Ther. 2009;123:334–43.
Bear DM, Kessler RM. United States Patent 8,883,831; 2014a.
Bear DM, Kessler RM. US Patent Application PCT/US2014/013874. Washington, DC; 2014b.
Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionefscu DF, Alpert JE, Soskin DP, Fava M. Randomized, proof of concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. J Affect Disord. 2017;208:6–14.
Berrocos E, Sanchez-Blazquez P, Garzón J, Mico JA. Opiates as antidepressants. Curr Pharm Design. 2009;15:1612–22.
Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid—acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016;46(2):53–8.
Snyder CB, Pert SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179(4077):1011–4.
Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav. 2003;43(1):60–6.
Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.
Dickenson AH. NMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand. 1997;41(1 Pt 2):112–5.
Schwartz-Lifshitz M, Zalsman G, Giner L, Oquendo MA. Can we really prevent suicide? Curr Psychiatry Rep. 2012;14(6):624–33.
Gross-Isseroff R, Dillon KA, Israeli M, Biegon A. Regionally selective increases in mu opioid receptor density in the brains of suicide victims. Brain Res. 1990;530(2):312–6.
Gabilondo AM, Meana JJ, García-Sevilla JA. Increased density of mu-opioid receptors in the postmortem brain of suicide victims. Brain Res. 1995;682(1–2):245–50.
Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006;63(11):1199–208.
Scarr E, Money TT, Pavey G, Neo J, Dean B. Mu opioid receptor availability in people with psychiatric disorders who died by suicide: a case control study. BMC Psychiatry. 2012;28(12):126.
Kosten T, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat. 1990;7:51–4.
Dean AJ, Bell J, Mascord DJ, Parker G, Christie MJ. A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. J Affect Disord. 2002;72:85–90.
Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19:510–3.
Fava M, Memisoglu A, Thase ME, Bodkin JA, Trivedi MH, de Somer M, Du Y, Leigh-Pemberton R, DiPetrillo L, Silverman B, et al. Opioid modulation with buprenorphine/samidorphan as adjunctive treatment for inadequate response to antidepressants: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2016;173(5):499–508.
Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 1987;26(9):1445–7.
Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010;1314:56–73.
Thase ME, Stanford AD, Memisoglu A, Martin W, Claxton A, Bodkin JA, Trivedi MH, Fava M, Pathak S. Long-term efficacy, safety and tolerability of adjunctive ALKS 5461 as adjunctive treatment in patients with major depressive disorder enrolled in an ongoing Phase 3 study: poster session presented at American Psychiatric Association annual meeting. NY: NYC; 2018.
Emrich HM, Vogt P, Herz A, Kissling W. Antidepressant effects of buprenorphine. Lancet. 1982;2(8300):709.
Morgan L, Calloway E. Buprenorphine responders. Biol Psychiat. 1990;28(12):1078–80.
Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995;15(1):49–57.
Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol. 2008;28(5):593–5.
Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF 3rd. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in mid-life and older adults. J Clin Psychiatry. 2014;75(8):e785–93.
Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, Fava M. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology. 2015;40:1448–55.
Yowell Y, Bar G, Mashiah M, Baruch Y, Briskman I, Asherov J, Lotan A, Rigbi A, Panksepp J. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry. 2016;173(5):491–8.
Guerdjikova A, Walsh B, Shan K, Halseth AE, Dunayevich E, McElroy SL. Concurrent improvement in both binge eating and depressive symptoms with naltrexone/bupropion therapy in overweight or obese subjects with major depressive disorder in an open-label, uncontrolled study. Adv Ther. 2017;34(10):2307–15.
Murphy B, Ravichandran C, Babb SM, Cohen BM. Naltrexone in bipolar disorder with depression: a double-blind, placebo-controlled study. Clin Psychopharmacol. 2014;34(6):749–51.
Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275–85.
Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kögel B, Schiene K, Straßburger W, Terlinden R, Tzschentke TM. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012;13(10):1437–49.
Shapira NA, Verduin ML, DeGraw JD. Treatment of refractory major depression with tramadol monotherapy. J Clin Psychiatry. 2001;62(3):205–6.
Spencer C. The efficacy of intramuscular tramadol as a rapid-onset antidepressant. Aust N Z J Psychiatry. 2000;34(6):1032–3.
Rougemont-Bücking A, Gamma F, Panksepp J. Use of tramadol in psychiatric care: a comprehensive review and report of two cases. Swiss Med Wkly. 2017;147:w14428.
Press release 14 January 2009. E-therapeutics. http://www.firstwordpharma.com/node/39762#axzz54JR5qryu.
Press release 15 February 2016. E therapeutics https://www.fiercebiotech.com/biotech/e-therapeutics-reports-top-line-phase-iib-results-major-depressive-disorder.
Stanley B, Siever L. The Interpersonal Dimension of borderline personality disorder: toward a neuropeptide model. Am J Psychiatry. 2010;167:24–39.
Stanley B, Sher L, Wilson S, Ekman R, Huang YY, Mann JJ. Non suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord. 2010;124(1–2):134–40.
Bresin K, Gordon KH. Endogenous opioids and nonsuicidal self-injury: a mechanism of affect regulation. Neurosci Biobehav Rev. 2013;37(3):374–83.
Resnick R, Falk F. Buprenorphine: pilot trials in borderline patients and opiate dependence—treatment of a common disorder? Monograph. In: Harris LS, editor. Problems of drug dependence. Washington, DC: National Institute on Drug Abuse Research; 1987. p. 155–68.
Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353–9.
Shapira NA, Keck PE Jr, Goldsmith TD, et al. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety. 1997;6:170–3.
Goldsmith TB, Shapira NA, Keck PE Jr. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry. 1999;156:660–1.
Liddell Malcolm B, Aziz Victor, Briggs Patrick, Kanakkehewa Nimalee, Rawi Omar. Buprenorphine augmentation in the treatment of refractory obsessive–compulsive disorder. Ther Adv Psychopharmacol. 2013;3(1):15–9.
Ahmadpanah M, Reihani A, Ghaleiha A, Soltanian A, Haghighi M, Jahangard L, Sadeghi Bahmani D, Holsboer-Trachsler E, Brand S. Buprenorphine augmentation improved symptoms of OCD, compared to placebo—results from a randomized, double-blind and placebo-controlled clinical trial. J Psychiatr Res. 2017;94:23–8.